Gilead Sciences | GILD - Selling And Administration Expenses


Gilead Sciences reported $1.45B in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.58B 316M Mar/2026
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
ALKERMES USD 264.59M 77.4M Mar/2026
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
Amgen USD 1.58B 354M Mar/2026
Biogen USD 554.3M 128.2M Mar/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Coherus Biosciences USD 15M 6.26M Dec/2025
Eli Lilly USD 2.93B 198M Mar/2026
Gilead Sciences USD 1.45B 326M Mar/2026
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Glaxosmithkline GBP 3.56B 650.29M Dec/2025
Incyte USD 328.1M 62.31M Mar/2026
J&J USD 6.03B 719M Mar/2026
Merck USD 2.67B 180M Mar/2026
Moderna USD 173M 135M Mar/2026
Neurocrine Biosciences USD 318.5M 16.7M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.33B 419M Mar/2026
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
United Therapeutics USD 156.6M 34M Mar/2026
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026